MICOT PHARMA-B (02335) Selected for Hang Seng Composite Index Inclusion

Stock News

Aug 24

MICOT PHARMA-B (02335) has announced its selection for inclusion as a constituent stock of the Hang Seng Composite Index, following the quarterly index review results released by Hang Seng Indexes Company Limited on August 21, 2026, covering the period ending June 30, 2026. The inclusion will take effect from September 7, 2026.

Upon becoming a constituent of the Hang Seng Composite Index, the company's H-shares are expected to qualify for inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. These channels serve as vital pathways for investors from mainland China's capital markets to conduct stock trading and investment activities in Hong Kong.

The board believes that this inclusion reflects the capital market's recognition of the company's value and growth potential. This development is anticipated to broaden the company's shareholder base and enhance the trading liquidity of its H-shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1122580555"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122580555\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122580555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-24 12:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122580555","market":"us","top_or_hot":-1,"title":"MICOT PHARMA-B (02335) Selected for Hang Seng Composite Index Inclusion","media":"Stock News","content":"<p>MICOT PHARMA-B (02335) has announced its selection for inclusion as a constituent stock of the Hang Seng Composite Index, following the quarterly index review results released by Hang Seng Indexes Company Limited on August 21, 2026, covering the period ending June 30, 2026. The inclusion will take effect from September 7, 2026.<br><br>Upon becoming a constituent of the Hang Seng Composite Index, the company's H-shares are expected to qualify for inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. These channels serve as vital pathways for investors from mainland China's capital markets to conduct stock trading and investment activities in Hong Kong.<br><br>The board believes that this inclusion reflects the capital market's recognition of the company's value and growth potential. This development is anticipated to broaden the company's shareholder base and enhance the trading liquidity of its H-shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MICOT PHARMA-B (02335) Selected for Hang Seng Composite Index Inclusion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMICOT PHARMA-B (02335) Selected for Hang Seng Composite Index Inclusion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-24 12:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MICOT PHARMA-B (02335) has announced its selection for inclusion as a constituent stock of the Hang Seng Composite Index, following the quarterly index review results released by Hang Seng Indexes Company Limited on August 21, 2026, covering the period ending June 30, 2026. The inclusion will take effect from September 7, 2026.<br><br>Upon becoming a constituent of the Hang Seng Composite Index, the company's H-shares are expected to qualify for inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. These channels serve as vital pathways for investors from mainland China's capital markets to conduct stock trading and investment activities in Hong Kong.<br><br>The board believes that this inclusion reflects the capital market's recognition of the company's value and growth potential. This development is anticipated to broaden the company's shareholder base and enhance the trading liquidity of its H-shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCI","symbol_name":"恒生综合指数","start_time":0,"source_url":"","article_id":"1122580555","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122580555","pubTimestamp":1787544854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MICOT PHARMA-B (02335) has announced its selection for inclusion as a constituent stock of the Hang Seng Composite Index, following the quarterly index review results released by Hang Seng Indexes...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSCI":"恒生综合指数","02335":"麦科医药-B","BK1161":"生物科技"},"translate_title":"MICOT PHARMA-B (02335) 获选纳入恒生综合指数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSCI":1,"02335":1},"content_text":"MICOT PHARMA-B (02335) has announced its selection for inclusion as a constituent stock of the Hang Seng Composite Index, following the quarterly index review results released by Hang Seng Indexes Company Limited on August 21, 2026, covering the period ending June 30, 2026. The inclusion will take effect from September 7, 2026.Upon becoming a constituent of the Hang Seng Composite Index, the company's H-shares are expected to qualify for inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. These channels serve as vital pathways for investors from mainland China's capital markets to conduct stock trading and investment activities in Hong Kong.The board believes that this inclusion reflects the capital market's recognition of the company's value and growth potential. This development is anticipated to broaden the company's shareholder base and enhance the trading liquidity of its H-shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}